Extracted from this filing and checked against the source text.
Debt Financings
SEC 8-K Item 2.03/2.04
confidence 0.9
IGC Pharma, Inc. incurred credit facility of up to USD$12,000,000.00 with O-Bank, CO., LTD. at interest rate mentioned in the Certificate of Deposit, as the case may be, plus maturing first anniversary of the Effective Date.
- Instrument
- credit facility
- Principal
- up to USD$12,000,000.00
- Counterparty
- O-Bank, CO., LTD.
- Rate
- interest rate mentioned in the Certificate of Deposit, as the case may be, plus
- Maturity
- first anniversary of the Effective Date
- Event
- incurrence
Exact text from the filing
On June 30, 2023, (the “Effective Date”), IGC Pharma, Inc. (“IGC” or “Borrower”) entered into a Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the “Loan Agreement”) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the “Lender’) pursuant to which the Borrower may borrow up to USD$12,000,000.00 only or the equivalent thereof in other major currencies (the “Credit Facility”).
View on SEC.gov
Material Agreements
SEC 8-K Item 1.01/1.02
confidence 0.9
IGC Pharma, Inc. entered into Loan Agreement with O-Bank, CO., LTD. valued at up to USD$12,000,000.00 (effective 2023-06-30).
- Action
- entry
- Agreement
- credit facility
- Counterparty
- O-Bank, CO., LTD.
- Value
- up to USD$12,000,000.00
- Effective
- 2023-06-30
Exact text from the filing
On June 30, 2023, (the “Effective Date”), IGC Pharma, Inc. (“IGC” or “Borrower”) entered into a Master Loan and Security Agreement along with the General Banking Facility Letter (collectively called the “Loan Agreement”) with O-Bank, CO., LTD., a banking corporation incorporated under the laws of Taiwan, as administrative agent and lender (the “Lender’) pursuant to which the Borrower may borrow up to USD$12,000,000.00 only or the equivalent thereof in other major currencies (the “Credit Facility”).
View on SEC.gov